Nektar Therapeutics Stock Forecast, Price & News

Nektar Therapeutics' stock was trading at $16.47 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NKTR shares have decreased by 3.8% and is now trading at $15.84.
View which stocks have been most impacted by COVID-19.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 sell rating, 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Nektar Therapeutics.

Nektar Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Nektar Therapeutics.

Nektar Therapeutics will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Nektar Therapeutics (NASDAQ:NKTR) released its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.69) by $0.24. The biopharmaceutical company earned $48.85 million during the quarter, compared to analyst estimates of $22.76 million. Nektar Therapeutics had a negative return on equity of 28.23% and a negative net margin of 264.38%. The business's revenue for the quarter was up 109.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.63) earnings per share.
View Nektar Therapeutics' earnings history.

15 brokerages have issued 1-year target prices for Nektar Therapeutics' stock. Their forecasts range from $17.00 to $80.00. On average, they anticipate Nektar Therapeutics' stock price to reach $31.23 in the next twelve months. This suggests a possible upside of 97.2% from the stock's current price.
View analysts' price targets for Nektar Therapeutics.

Some companies that are related to Nektar Therapeutics include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Eli Lilly and (LLY), Zoetis (ZTS), Horizon Therapeutics Public (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Advanced Micro Devices (AMD), Bristol-Myers Squibb (BMY), Netflix (NFLX) and Incyte (INCY).

Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."

Nektar Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rhenman & Partners Asset Management AB (0.56%), Retirement Systems of Alabama (0.13%), Assenagon Asset Management S.A. (0.11%), State of New Jersey Common Pension Fund D (0.07%), Comerica Bank (0.06%) and DAVENPORT & Co LLC (0.03%). Company insiders that own Nektar Therapeutics stock include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Jonathan Zalevsky, Katharina Otto-Bernstein, Lutz Lingnau, Maninder Hora, Mark Andrew Wilson, R Scott Greer, Robert Chess and Stephen K Doberstein.
View institutional ownership trends for Nektar Therapeutics.

NKTR stock was sold by a variety of institutional investors in the last quarter, including KBC Group NV, WINTON GROUP Ltd, New Mexico Educational Retirement Board, Nisa Investment Advisors LLC, New Mexico Educational Retirement Board, DAVENPORT & Co LLC, Franklin Street Advisors Inc. NC, and BNP Paribas Arbitrage SA. Company insiders that have sold Nektar Therapeutics company stock in the last year include Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, Jonathan Zalevsky, Mark Andrew Wilson, R Scott Greer, and Robert Chess.
View insider buying and selling activity for Nektar Therapeutics.

NKTR stock was acquired by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Assenagon Asset Management S.A., DekaBank Deutsche Girozentrale, Pacer Advisors Inc., Ropes Wealth Advisors LLC, Avantax Advisory Services Inc., Exchange Traded Concepts LLC, and Contravisory Investment Management Inc..
View insider buying and selling activity for Nektar Therapeutics.

Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NKTR stock can currently be purchased for approximately $15.84.

Nektar Therapeutics has a market capitalization of $2.83 billion and generates $114.62 million in revenue each year. The biopharmaceutical company earns $-440,670,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis. Nektar Therapeutics employs 723 workers across the globe.

The official website for Nektar Therapeutics is www.nektar.com.

Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]